Neuropsychological outcome of children treated for standard risk medulloblastoma in the PNET4 European randomised controlled trial of hyperfractionated versus standard radiotherapy and maintenance chemotherapy

Purpose<p style="box-sizing: border-box; margin: 0px 0px 16px; padding: 0px;">In the European HIT-SIOP PNET4 randomized controlled trial, children with standard risk medulloblastoma were allocated to hyperfractionated radiation therapy (HFRT arm, including a partially focused boost)...

Full description

Bibliographic Details
Main Authors: Câmara-Costa, Hugo (Author), Resch, Anika (Author), Kieffer, Virginie (Author), Lalande, Clémence (Author), Poggi, Geraldina (Author), Kennedy, Colin (Author), Bull, Kim (Author), Calaminus, Gabriele (Author), Grill, Jacques (Author), Doz, François (Author), Rutkowski, Stefan (Author), Massimino, Maura (Author), Kortman, Rolf-Dieter (Author), Lannering, Birgitta (Author), Dellatolas, Georges (Author), Chevignard, Mathilde (Author)
Format: Article
Language:English
Published: 2015-08-01.
Subjects:
Online Access:Get fulltext
Description
Summary:Purpose<p style="box-sizing: border-box; margin: 0px 0px 16px; padding: 0px;">In the European HIT-SIOP PNET4 randomized controlled trial, children with standard risk medulloblastoma were allocated to hyperfractionated radiation therapy (HFRT arm, including a partially focused boost) or standard radiation therapy (STRT arm), followed, in both arms, by maintenance chemotherapy. Event-free survival was similar in both arms. Previous work showed that the HFRT arm was associated with worse growth and better questionnaire-based executive function, especially in children <8 years of age at diagnosis. Therefore, the aim of this study was to compare performance-based cognitive outcomes between treatment arms.</p>Methods and Materials<p style="box-sizing: border-box; margin: 0px 0px 16px; padding: 0px;">Neuropsychological data were collected prospectively in 137 patients. Using the Wechsler Intelligence Scales, Kaufman Assessment Battery for Children, and Raven's Progressive Matrices, we estimated full-scale intelligence quotient (FSIQ) and, when available, verbal IQ (VIQ), performance IQ (PIQ), working memory index (WMI), and processing speed index (PSI).</p>Results<p style="box-sizing: border-box; margin: 0px 0px 16px; padding: 0px;">Among the 137 participants (HFRT arm n=71, STRT arm n=66, 63.5% males), mean (±SD) ages at diagnosis and assessment respectively were 9.3 (±3.2) years of age (40.8% < 8 years of age at diagnosis) and 14.6 (±4.3) years of age. Mean (±SD) FSIQ was 88 (±19), and mean intergroup difference was 3.88 (95% confidence interval: −2.66 to 10.42, <em style="box-sizing: border-box; margin: 0px; padding: 0px;">P</em>=.24). No significant differences were found in children >8 years of age at diagnosis. In children <8 years of age at diagnosis, a marginally significant trend toward higher VIQ was found in those treated in the HFRT arm; a similar trend was found for PSI but not for PIQ, WMI, or FSIQ (mean intergroup differences were: 12.02 for VIQ [95% CI: 2.37-21.67; <em style="box-sizing: border-box; margin: 0px; padding: 0px;">P</em>=.02]; 3.77 for PIQ [95% CI: −5.19 to 12.74; <em style="box-sizing: border-box; margin: 0px; padding: 0px;">P</em>>.10]; 5.20 for WMI [95% CI: −2.07 to 12.47; <em style="box-sizing: border-box; margin: 0px; padding: 0px;">P</em>>.10]; 10.90 for PSI [95% CI: −1.54 to 23.36; <em style="box-sizing: border-box; margin: 0px; padding: 0px;">P</em>=.08]; and 5.28 for FSIQ [95% CI: −4.23 to 14.79; <em style="box-sizing: border-box; margin: 0px; padding: 0px;">P</em>>.10]).</p>Conclusions<p style="box-sizing: border-box; margin: 0px 0px 16px; padding: 0px;">HFRT was associated with marginally higher VIQ in children <8 years of age at diagnosis, consistent with a previous report using questionnaire-based data. However, overall cognitive ability was not significantly different.</p>